Vasorum’s Celt ACD PLUS Receives FDA Green Light for Market Use
Vasorum Secures FDA Approval for Celt ACD PLUS Device
First Commercial Cases Successfully Completed
Vasorum USA, Inc, a pioneering medical device company, has proudly announced the approval of its Celt ACD PLUS System by the U.S. Food and Drug Administration (FDA). This cutting-edge vascular closure device harnesses Blood Signal technology to enhance the already impressive Celt ACD platform. With this innovation, physicians now have a visual indicator for placement and closure, which is particularly crucial in scenarios where ultrasound imaging isn’t accessible.
Innovative Features of Celt ACD PLUS
The Celt ACD PLUS represents a groundbreaking advancement in small-bore closure devices, available in 5F, 6F, and 7F sizes. It is specifically designed for swift arterial puncture closure following catheter-based vascular procedures. The device's unique mechanism significantly minimizes major complications—such as bleeding and hematomas—related to vascular closures. Recent clinical data have highlighted substantial improvements in time to hemostasis, ambulation, and discharge, contributing to enhanced efficiency and cost savings in post-anesthesia care.
First Successful Deployments
Notably, the first commercial cases involving the Celt ACD PLUS device were completed at a renowned vascular institute. Leading this initiative was Dr. Joseph Ricotta, a well-respected figure in vascular surgery and the program director of the vascular surgery fellowship at a prominent medical school.
Dr. Ricotta noted, "The Celt ACD PLUS represents a significant advancement in vascular closure, enabling accurate deployment through a visible indicator. It shortens the learning curve for new users, thereby expanding access to this technology. The device is particularly useful in contexts lacking ultrasound guidance, ensuring reliability across various clinical environments."
Vasorum's Commitment to Innovation
David Gunther, Vice President of Sales and Marketing at Vasorum, emphasized the company's unwavering commitment to transforming vascular closure technology. He stated, "The FDA approval of Celt ACD PLUS signifies an exciting milestone for Vasorum and the medical professionals we support. By bolstering the safety and efficiency of arterial closure, we continue to demonstrate our commitment to innovation and enhance procedural outcomes for healthcare providers and patients alike."
Market Potential for Vascular Closure Devices
The U.S. market for small-bore arterial vascular closure devices, valued at approximately $600 million, is anticipated to reach $1 billion by the end of the next decade. This significant growth aligns with the increasing rates of cardiovascular disease, primarily driven by an aging populace and a rise in obesity, diabetes, and hypertension cases.
Moreover, as healthcare trends lean towards outpatient procedures—including those at ambulatory surgical centers—demand for efficient closure solutions rises. While many hospitals have shifted to radial access for coronary interventions, femoral access remains essential for peripheral procedures. In quick-paced environments, fast hemostasis enables timely discharges, enhancing operational efficiency and boosting revenue.
Emphasizing Patient-Centric Care
As healthcare increasingly prioritizes same-day discharges and cost-effective treatment models, vascular closure devices like the Celt ACD PLUS are pivotal in streamlining workflows and improving patient outcomes.
About Vasorum
Established in 2007, Vasorum Ltd. is devoted to innovating solutions that redefine vascular closure. The Celt ACD is a foundational technology aimed at addressing a wide range of interventional procedures. The company is headquartered in Dublin, with operational perspectives extending into the United States.
For additional information, please reach out to:
Scott Kraus
Chief Executive Officer
©2025 Vasorum USA, Inc. All rights reserved.
Frequently Asked Questions
What is the Celt ACD PLUS system?
The Celt ACD PLUS is an advanced vascular closure device designed for rapid arterial puncture closure following various vascular procedures.
Who was involved in the first commercial deployments?
The first successful cases were completed by Dr. Joseph Ricotta at a well-known vascular institute.
What are the key advantages of the Celt ACD PLUS?
The device features Blood Signal technology, offering visual indicators for precision in deployment and closure, reducing complications significantly.
Why is the vascular closure device market growing?
The market is expanding due to the rising prevalence of cardiovascular diseases and the increasing adoption of outpatient procedures that demand efficient closure solutions.
How does Vasorum contribute to healthcare innovation?
Vasorum focuses on developing advanced vascular closure technologies that improve safety, efficiency, and patient outcomes, reflecting their commitment to healthcare innovation.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
